



## New antifungal tetrahydrofuran derivatives from a marine sponge-associated fungus *Aspergillus* sp. LS78

Yang Liu, Lijian Ding\*, Ziming Zhang, Xiaojun Yan, Shan He\*

Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo 315832, People's Republic of China



### ARTICLE INFO

#### Keywords:

Tetrahydrofuran derivatives  
Aspericacid  
*Aspergillus*  
Sponge-associated  
Antifungal

### ABSTRACT

Two new tetrahydrofuran derivatives named aspericacids A and B (1 and 2) were isolated from the metabolites produced by the sponge-associated *Aspergillus* sp. LS78. They represented an unusual type of tetrahydrofuran derivatives, possessing 2,5-disubstituted tetrahydrofuran ring coupled with a chain unsaturated fatty acid. The planar structures of 1 and 2 were determined by HRESIMS, 1D and 2D NMR spectroscopy. The absolute configuration of 1 was assigned using both experimental and computational electronic circular dichroism (ECD). In addition, aspericacid A (1) exhibited *in vitro* antifungal activity (MIC = 50 µg/mL), but 2 showed not significantly activity against any of the tested strains with the MIC values of 128 µg/mL.

### 1. Introduction

The increasing number of drug-resistant fungal pathogen strains has become resistant to commonly used antifungal drugs in recent years [1]. For some opportunistic human pathogens who caused superficial and systemic infections exemplified by *Candida albicans* and *Cryptococcus neoformans*, experimental data clearly indicated that it was resistant to conventional antifungal agents, and infections caused by it were difficult to cure with conventional antifungal drugs [2–4]. Hence, novel classes of antibiotics that can effectively resist drug-resistant fungi or adjuvants that could restore antibiotic sensitivity are urgently needed, which prevent our ability to control fungal infections from collapsing. The *Aspergillus* genus, a genus can produce diverse secondary metabolites, were renowned for its commercial and medical importance [5,6]. Some species can produce devastating toxins such as aflatoxins, but also many others in *Aspergillus* have been a pivotal sources of mass-produced industrial enzymes and lifesaving drugs like lovastatin [7]. Various types of novel bioactive metabolites have been reported from this genus, including polyketides [8–10], alkaloids [11–13], terpenes [14], steroids [15–17], halides [18], and peptides [12,19,20]. Excitingly, some metabolites among of them were potent and selective inhibitors for fungal protein synthesis such as aspirochlorines [21].

In our continuous investigations of new antifungal lead drugs produced by marine sponge-associated microbes [22], the ethyl acetate extract of the marine-associated *Aspergillus* sp. LS78 was revealed the

presence of moderate antifungal activity against *C. albicans* and *C. neoformans*. A further chemical study on its secondary metabolites resulted in the identification of a pair of new tetrahydrofuran derivatives named aspericacids A and B (1 and 2). Herein, we described the isolation and structure elucidation, involving comparison of experimental and calculated electronic circular dichroism (ECD) spectra, along with the *in vitro* anti-fungal activity assessment of these compounds.

### 2. Experimental

#### 2.1. General experimental procedures

Nuclear Magnetic Resonance (NMR) spectra were obtained on a Varian 600 MHz (Palo Alto, CA, USA) at room temperature, using solvent signal (CDCl<sub>3</sub>: δ<sub>H</sub> 7.26/δ<sub>C</sub> 77.0) as reference. HRESIMS data were recorded using an Agilent Technologies 6224 Q – TOF LC/MS spectrometer, which equipped with an ESI-ion source (Agilent Technologies, Santa Clara, CA, USA). UV data were measured on a NADE Evolution 201 spectrophotometer (Thermo Fisher, Waltham, MA, USA). IR experiments were carried out on a Nicolet iS5 spectrometer (Thermo Fisher, Waltham, MA, USA). CD spectra were carried out on JASCO J-810 Circular Dichroism spectrometer (Jasco Inc., Tokyo, Japan). Sephadex LH20 (25–100 µm, Pharmacia, Uppsala, Sweden) and silica gel (200–300 mesh, Qingdao Marine Chemical Co. Ltd., Qingdao, China) were used for CC (column chromatography). Medium-pressure liquid chromatography (MPLC) was performed using

\* Corresponding authors.

E-mail addresses: [dinglijian@nbu.edu.cn](mailto:dinglijian@nbu.edu.cn) (L. Ding), [heshan@nbu.edu.cn](mailto:heshan@nbu.edu.cn) (S. He).

<https://doi.org/10.1016/j.fitote.2020.104677>

Received 6 May 2020; Received in revised form 15 June 2020; Accepted 16 June 2020

Available online 19 June 2020

0367-326X/ © 2020 Elsevier B.V. All rights reserved.

ODS column on FLEXA Purification System (Agela Technologies, Tianjin, China). Semi-preparative HPLC was conducted on a Waters HPLC instrument (Waters 600, Milford, MA, USA) equipped with a Waters 2996 detector and combined with C<sub>18</sub> column (YMC-Pack ODS-A, 250 × 10 mm, 5 μm, Tokyo, Japan).

## 2.2. Fungal material

The fungal strain in this work was obtained from the tissue of sponge *Haliclona* sp. collected at Lingshui, Hainan Province, China. Based on morphology, combined with the internal transcribed spacer region (ITS) sequencing (GenBank accession ID: EU645719, 99% similarity), the fungal strain LS78 was identified eventually as *Aspergillus* sp. Detailed procedure was that the DNA fragment of the fungal ITS regions was amplified using polymerase chain reaction (PCR) with the pair of primers ITS1 (5'-TCC GTA GGT GAA CCT GCG G-3') and ITS4 (5'-TCC TCC GCT TAT TGA TAT GC-3') in reaction system. Finally, the correct PCR product was verified by gel electrophoresis and then submitted to Sangon Biotech (Shanghai) Co., Ltd. for sequencing. A voucher specimen (No. LS78) was deposited with the PDB medium at Ningbo University, Ningbo, China.

## 2.3. Fermentation, extraction and isolation

The purified fungal strain *Aspergillus* sp. was initially cultured on potato dextrose agar (PDA, containing potato extract 8.0 g, dextrose 20 g, artificial sea salt 35 g, agar 20 g and distilled water 1 L) at 25 °C for 7 days. A single colony was inoculated into 250 mL Erlenmeyer flasks containing 100 mL PDB medium on a rotary shaker (180 rpm, 28 °C) for three days. Subsequently, the seed culture was equally transferred to 40 × 1000 mL flask containing rice medium (200 g of rice, 200 mL of water, and 35 g of sea salt). A large-up fermentation was processed under static condition for 35 days at 25 °C. Then, the whole broth of finished fermentation was extracted with EtOAc for three times and concentrated under reduced pressure to obtain a crude extract (15 g). The crude extract was divided into 4 fractions (Fr.1 – Fr.4) using chromatographed on a Sephadex LH-20 column eluting with CH<sub>3</sub>OH and CH<sub>2</sub>Cl<sub>2</sub> (1:1, v/v). Fraction 3 was subjected to vacuum liquid chromatography on silica gel column (6 × 15 cm, 200–300 mesh) using a gradient of mixed petroleum ether/EtOAc (form 20:1 to 0:1, v/v) to yield eight subfractions (Fr.3.A – Fr.3.H), and the resulting subfraction Fr.3.F was further performed on MPLC (40–100% MeOH/H<sub>2</sub>O, flow rate 20 mL/min, 120 min) to obtain 6 fractions (Fr.3.F.1 – Fr.3.F.6). Further, Fr.3.F.6 was purified by semi-preparative HPLC with UV detection at 200 nm to yield 1 (2.0 mg) and 2 (1.3 mg).

Aspericacid A (1): Yellow wax; [α]<sub>D</sub><sup>25</sup> + 7.00 (c 0.15, MeOH); ECD (c 11.82 × 10<sup>-4</sup> M, MeOH) λ<sub>ext</sub> (Δε) 233 (+6.78), 250 (+0.25), 29 (+2.93) nm; UV (MeOH) λ<sub>max</sub> (log ε) 204.5 (3.60), 238 (3.47), 277.5 (3.47); IR (KBr) ν<sub>max</sub> 3400, 2963, 2931, 2874, 1713, 1610, 1459, 1377, 1266, 1202, 1166, 1045, 1023, 802 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz) and <sup>13</sup>C NMR (CDCl<sub>3</sub>, 150 MHz) data, see Table 1; HRESIMS *m/z* [M + NH<sub>4</sub>]<sup>+</sup> peak at 321.2069 (calculated for C<sub>16</sub>H<sub>30</sub>NO<sub>4</sub>).

Aspericacid B (2): Pale yellow wax; [α]<sub>D</sub><sup>25</sup> -2.54 (c 0.37, MeOH); UV (MeOH) λ<sub>max</sub> (log ε) 220.5 (4.58); IR (KBr) ν<sub>max</sub> 3419, 2974, 2935, 2874, 1711, 1459, 1381, 1258, 1195, 1089, 1028, 955, 800, 754 cm<sup>-1</sup>; <sup>1</sup>H NMR and <sup>13</sup>C NMR data, see Table 1. HRESIMS *m/z* [M + H]<sup>+</sup> peak at 285.2064 (calculated for C<sub>16</sub>H<sub>29</sub>O<sub>4</sub>).

## 2.4. Antifungal assay

Aspericacids A and B (1 and 2) were tested for their antifungal activities against *C. albicans* and *C. neoformans* based on the previously described method [23]. Briefly, the SDA medium were prepared, the two indicator strains (*C. neoformans* and *C. albicans*) were incubated at 30 °C for 16–20 h based on the growth appearance. All compounds were dissolved in dimethyl sulfoxide. The stock solution (12.8 mg/mL) was

**Table 1**  
<sup>1</sup>H (600 MHz) and <sup>13</sup>C NMR (150 MHz) data for 1 and 2 (CDCl<sub>3</sub>, δ in ppm, J in Hz).

NO.	1		2	
	δ <sub>C</sub> , type	δ <sub>H</sub> (J in Hz)	δ <sub>C</sub> , type	δ <sub>H</sub> (J in Hz)
1	180.6, C	-	181.8, C	-
2	37.3, CH	2.45, m	37.7, CH	2.39, m
3a	41.1, CH <sub>2</sub>	1.71, m;	41.0, CH <sub>2</sub>	1.68, m;
3b	-	1.40, m	-	1.38, m
4	30.1, CH	2.50, m	30.3, CH	2.48, m
5	131.8, CH	5.22, d (9.6)	131.8, CH	5.20, d (9.6)
6	134.0, C	-	134.0, C	-
7	85.5, CH	4.31, t (7.0)	82.6, CH	4.33, t (7.6)
8a	30.5, CH <sub>2</sub>	1.77, m	30.7, C	2.00, m;
8b	-	1.92, m;	-	1.74, m
9a	34.6, CH <sub>2</sub>	2.21, m;	30.5, CH <sub>2</sub>	2.12, m;
9b	-	1.74, m	-	1.52, m
10	88.8, C	-	86.3, C	-
11	213.8, C	-	72.3, CH	3.79, q (6.4)
12	24.7, CH <sub>3</sub>	2.25, s	17.4, CH <sub>3</sub>	1.15, d (6.7)
13	17.2, CH <sub>3</sub>	1.16, d (6.9)	17.4, CH <sub>3</sub>	1.15, d (6.7)
14	21.0, CH <sub>3</sub>	0.96, d (6.6)	21.1, CH <sub>3</sub>	0.97, d (6.6)
15	11.9, CH <sub>3</sub>	1.63, s	12.2, CH <sub>3</sub>	1.64, s
16	23.9, CH <sub>3</sub>	1.38, s	23.1, CH <sub>3</sub>	1.17, s

diluted with RPMI-1640 medium (Roswell Park Memorial Institute) with a serial 2-fold dilution to concentrations from 0.256 to 256 μg/mL in the 96-well plates. Each well was inoculated with 20 μL of homogeneous suspensions. Then the plates were incubation at 35 °C for 70 h. A culture supplemented with 8 μg/mL fluconazole was used as positive control. The culture containing DMSO (0.5%) was used as a negative control. The MIC (Minimal Inhibit Concentration) was assessed at the lowest concentration at which the test compound inhibits fungal growth.

## 3. Results and discussion

Aspericacid A (1) was obtained as a yellow wax. The HRESIMS of 1 (Fig. S9) showed the [M + NH<sub>4</sub>]<sup>+</sup> peak at *m/z* 300.1272, established the molecular formula as C<sub>16</sub>H<sub>26</sub>O<sub>4</sub> indicating four degrees of unsaturation. The IR spectrum revealed the presence of a carboxylic acid (1713 cm<sup>-1</sup> and 3400 cm<sup>-1</sup>). The <sup>1</sup>H NMR and HSQC spectrum of 1 (Table 1) indicated resonances attributable to one olefinic proton (δ<sub>H</sub> 5.22, 1H, d, J = 9.6 Hz, H-5), one oxymethine proton (δ<sub>H</sub> 4.31, 1H, t, J = 7.0 Hz, H-7), two methine protons (δ<sub>H</sub> 2.45, 1H, m, H-4; δ<sub>H</sub> 2.50, 1H, m, H-2), three pairs of methylene protons [(δ<sub>H</sub> 2.21, 1H, m, H-9a; δ<sub>H</sub> 1.74, 1H, m, H-9b), (δ<sub>H</sub> 1.77, 1H, m, H-8a; δ<sub>H</sub> 1.92, 1H, m, H-8b) and (δ<sub>H</sub> 1.71, 1H, m, H-3a; δ<sub>H</sub> 1.40, 1H, m, H-3b)], two methyls with doublet (δ<sub>H</sub> 1.16, 3H, d, J = 6.9 Hz, H<sub>3</sub>-13; δ<sub>H</sub> 0.96, 3H, d, J = 6.6 Hz, H<sub>3</sub>-14) and three methyls with singlet (δ<sub>H</sub> 2.25, 3H, s, H<sub>3</sub>-12; δ<sub>H</sub> 1.63, 3H, s, H<sub>3</sub>-15; δ<sub>H</sub> 1.38, 3H, s, H<sub>3</sub>-16). Analysis of <sup>13</sup>C NMR and DEPT spectrum data of 1 classified the 16 carbons into five methyls, three methylenes, four methines as well as four nonprotonated carbons.

Given the three of four degrees of unsaturation were attributed to the vinyl group at δ<sub>C</sub> 131.8 (C-5) and δ<sub>C</sub> 134.0 (C-6), two carbonyl signals at δ<sub>C</sub> 180.6 (C-1) and δ<sub>C</sub> 213.8 (C-11), the presence of a single ring was inferred from the last degree of unsaturation. Then the existence of the 2,5-disubstituted tetrahydrofuran ring was further confirmed by the COSY correlations of H-7/H-8/H-9 in conjunction with the HMBC correlation of H-8b/C-10 (δ<sub>C</sub> 88.8) as well as the observation of chemical shift at C-10 and C-7 (δ<sub>C</sub> 85.5) (Fig. 2, Figs. S4 and S6). Moreover, the HMBC correlations from H<sub>3</sub>-12/H<sub>3</sub>-16 to C-10 and from H<sub>3</sub>-16 to C-11 allowed the assignment of both the acetyl at C-11 and the methyl at C-16 (δ<sub>C</sub> 23.9) were tethered to C-10 in the tetrahydrofuran ring. A closer examination of the COSY spectrum constructed the 1,3-dimethyl-1,3-propanediyl by correlations of H-2/H<sub>2</sub>-3/H<sub>3</sub>-13 and H<sub>2</sub>-3/H-4/H<sub>3</sub>-14. One end of the residue of 1,3-dimethyl-1,3-propanediyl




Fig. 1. Chemical structures of compounds 1 and 2.




Fig. 2. Selected 2D NMR correlations for 1 and 2.




Fig. 3. Experimental ECD spectra in MeOH and the calculated ECD spectra of 1 at B3LYP-D3/def2-TZVP level.

was attached to a carboxylic acid at C-2 ( $\delta_C$  37.3) based on the HMBC correlation of H<sub>3</sub>-13/C-1. The chain unsaturated fatty acid moiety on the side chain of tetrahydrofuran was further verified by the HMBC correlation of H<sub>3</sub>-15/C-5 and COSY correlation of H-4/H-5. Subsequently, the crucial cross-peak of H<sub>3</sub>-15/C-7 in the HMBC spectrum established unambiguously the linkage of the unsaturated fatty acid

moiety to C-7 of the tetrahydrofuran ring (Fig. 2). Thus, the planar structure of aspericacid A (1) was elucidated as depicted in Fig. 1.

On account of the key NOE correlation of H<sub>3</sub>-12/H-7 (Fig. 2), the C-1 to C-6 chain and the Me-16 were located in the same face of the tetrahydrofuran ring. The *E*-configuration was appointed to the vinyl group between C-5 and C-6 based on the NOE correlation between H-5 and H-7. Then on the observation of NOE correlations of H-2/H<sub>3</sub>-15 and H-4/H<sub>3</sub>-15, the relative configuration of 1 was established as (2*S*\*,4*R*\*,7*R*\*,10*R*\*). To elucidate the absolute configuration of in 1, the ECD curve of 1 was recorded and compared with its stereoisomer calculated by the time-dependent density functional theory method (TDDFT) at the B3LYP/def2-TZVP level. In general, conformational analyses were carried out *via* random searching in the Sybyl-X2.0 using the MMFF94S force field with an energy cutoff of 6.0 kcal/mol [24]. The results showed nine lowest energy conformers for 1. Subsequently, the conformers were re-optimized using DFT at the B3LYP-D3/6-31G(d) level in MeOH using the polarizable conductor calculation model (SMD) by the GAUSSIAN 09 program [25]. The energies, oscillator strengths, and rotational strengths (velocity) of the first 30 electronic excitations were calculated using the TDDFT methodology at the B3LYP-D3/def2-TZVP level in MeOH. The ECD spectra were simulated by the overlapping Gaussian function (half the bandwidth at 1/e peak height, sigma = 0.30 for all) [26]. The Boltzmann-averaged computed ECD spectrum of the (2*S*,4*R*,7*R*,10*R*)-1 well matched with that experimental spectrum of 1 (Fig. 3). Thus, the absolute configuration for 1 was identified as 2*S*,4*R*,7*R*,10*R*.

Aspericacid B (2), a pale yellow wax, had a molecular formula of C<sub>16</sub>H<sub>28</sub>O<sub>4</sub>, determined by HR-ESI-MS ([M + H]<sup>+</sup> peak at *m/z* 285.2064) (Fig. S19). The <sup>1</sup>H and <sup>13</sup>C NMR data of 2 resembled those of

**1**, the appearance of an additional oxymethine ( $\delta_C$  72.3/ $\delta_H$  3.79) and the absence of a carbonyl unit ( $\delta_C$  213.8) indicated that compound **2** contained an oxymethine group at C-11 instead of ketonic carbonyl group, which was confirmed by correlations of H-9/C-11, from H<sub>3</sub>-12 and H<sub>3</sub>-16 to C-10 in HMBC experiment of **2** as shown in Fig. 2. According to the aforementioned information, the planar structure of **2** was established. The relative positions of the unsaturated fatty acid chain and Me-16 were located in the opposite of the tetrahydrofuran ring in compound **2**, based on the NOE correlation of H<sub>3</sub>-16/H-7. Its relative configuration for the stereogenic centers at C-2/C-4 was assigned to be the same as those of **1**, on the basis of the NOE correlations of H<sub>3</sub>-15/H-4 and H<sub>3</sub>-15/H-2 (Fig. S17). In addition, the chemical shift ( $\delta_C$  72.3) of C-11 revealed an *erythro* configuration according to the described rule that the <sup>13</sup>C NMR shift for the hydroxymethine carbon was  $\delta_C$  74.0 for a *threo* relationship, and  $\delta_C$  72.0 for an *erythro* configuration normally [27]. In light of the biosynthetic origin, the stereogenic centers of **2** were tentatively proposed to be 2S,4R,7R,10R,11R (Fig. 3).

Biosynthetically, aspericacids A and B (**1** and **2**) are presumably to be derived from polyketide pathway. In the sight of the side chain unsaturated fatty acid, the precursors of compounds **1** and **2** would be likely derived from acetyl CoA and malonyl CoA [28]. Moreover, the tetrahydrofuran core was created with the help of a series of reactions exemplify with decarboxylation, epoxidation step at olefin, and ring-opening of the epoxide with water followed by a cyclization [29,30].

The biological activities of aspericacids A and B (**1** and **2**) were initially assessed by *in vitro* antifungal assays against selected pathogenic fungal strains. The bioassay results showed that **1** possessed moderate inhibitory activities with MIC value of 50  $\mu$ g/mL against both *C. albicans* and *C. neoformans*, while compound **2** displayed slightly weak activity (MIC = 128  $\mu$ g/mL).

In summary, chemical investigation of sponge-derived fungus *Aspergillus* sp. has resulted in the purification and characterization of two new compounds, aspericacids A and B (**1** and **2**). Structurally, they represented a rare type of tetrahydrofuran derivatives, possessing 2,5-disubstituted tetrahydrofuran ring coupled with a chain unsaturated fatty acid unit, and the absolute stereochemistry was firstly determined using ECD experiment. Biogenetically, **1** and **2** are presumably to be derived from the polyketide pathway. In addition, compound **1** exhibited moderate inhibitory activity (50  $\mu$ g/mL) against both strains tested, while compound **2** displayed weak activity. Collectively, this study further enlarged the structurally diversity of occurring tetrahydrofuran derivatives.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Acknowledgments

This study was financially supported by the National Natural Science Foundation of China (41706167, 41776168), the National 111 Project of China (D16013), and the Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Development Fund.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.fitote.2020.104677>.

## References

- [1] M.C. Fisher, N.J. Hawkins, D. Sanglard, S.J. Gurr, Worldwide emergence of resistance to antifungal drugs challenges human health and food security, *Science* 360 (2018) 739–742.

- [2] C. Tsui, E.F. Kong, M.A. Jabra-Rizk, Pathogenesis of *Candida albicans* biofilm, *Pathog. Dis.* 74 (2016) ftw018.
- [3] M. Selvaraj, P. Pandurangan, N. Ramasami, S.B. Rajendran, S.N. Sangilimuthu, P. Perumal, Rajendran, Highly potential antifungal activity of quantum-sized silver nanoparticles against *Candida albicans*, *Appl. Biochem. Biotechnol.* 173 (2014) 55–56.
- [4] M. Cogliati, A. Prigitano, M.C. Esposto, L. Romanò, A. Grancini, A.M. Tortorano, Epidemiological trends of *cryptococcosis* in Italy: molecular typing and susceptibility pattern of *Cryptococcus neoformans* isolates collected during a 20-year period, *Med. Mycol.* 56 (2018) 963–971.
- [5] H.W. Zhang, X.L. Bai, M. Zhang, J.W. Chen, H. Wang, Bioactive natural products from endophytic microbes, *Nat. Prod. J.* 8 (2018) 86–108.
- [6] X.L. Zhang, Z. Li, J.T. Gao, Chemistry and biology of secondary metabolites from *Aspergillus* genus, *Nat. Prod. J.* 8 (2018) 275–304.
- [7] J.F. Sanchez, A.D. Somoza, N.P. Keller, C.C.C. Wang, Advances in *Aspergillus* secondary metabolite research in the post-genomic era, *Nat. Prod. Rep.* 29 (2012) 351–371.
- [8] L.H. Zhang, B.M. Feng, Y.Q. Zhao, Y. Sun, B. Liu, F. Liu, G. Chen, J. Bai, H.M. Hua, H.F. Wang, Y.H. Pei, Polyketide butenolide, diphenyl ether, and benzophenone derivatives from the fungus *Aspergillus flavipes* PJO3-11, *Bioorg. Med. Chem. Lett.* 26 (2016) 346–350.
- [9] X.W. Du, D. Liu, J. Huang, C.J. Zhang, P. Peter, W.H. Lin, Polyketide derivatives from the sponge associated fungus *Aspergillus europaeus* with antioxidant and NO inhibitory activities, *Fitoterapia* 130 (2018) 190–197.
- [10] G.P. Yin, Y.R. Wu, M.H. Yang, T.X. Li, X.B. Wang, M.M. Zhou, J.L. Lei, L.Y. Kong, Four dimeric aromatic polyketides with new carbon skeletons from the fungus *Aspergillus* sp, *Org. Lett.* 19 (2017) 4058–4061.
- [11] J.R. Gubiani, M.C.S. Oliveira, R.A.R. Neponuceno, M.J. Camargo, W.S. Garcez, A.R. Biz, M.A. Soares, A.R. Araujo, V.S. Bolzani, H.C.F. Lisboa, T.A.N. Ribeiro, J.M. Oliveria, T.P. Banzato, L.G. Vasconcelos, C.A. Lima, G.B. Longato, J.M. Batista, H.L. Teles, Cytotoxic prenylated indole alkaloid produced by the endophytic fungus *Aspergillus terreus* P63, *Phytochem. Lett.* 32 (2019) 162–167.
- [12] X.W. Luo, C.M. Chen, H.M. Tao, X.P. Lin, B. Yang, X.F. Zhou, Y.H. Liu, Structurally diverse diketopiperazine alkaloids from the marine-derived fungus *Aspergillus versicolor* SCSIO 41016, *Org. Chem. Front.* 6 (2019) 736–740.
- [13] M.H. Chen, R.Z. Wang, W.L. Zhao, L.Y. Yu, C.H. Zhang, S.S. Chang, Y. Li, T. Zhang, J.G. Xing, M.L. Gan, F. Feng, S.Y. Si, Isocoumarindole A, a chlorinated isocoumarin and indole alkaloid hybrid metabolite from an endolichenic fungus *Aspergillus* sp, *Org. Lett.* 21 (2019) 1530–1533.
- [14] H.J. Lacey, C.L.M. Gilchrist, A. Crombie, J.A. Kalaitzis, D. Vuong, P.J. Rutledge, P. Turner, J.I. Pitt, E. Lacey, Y.H. Chooi, A.M. Piggott, Nanangenes: drimane sesquiterpenoids as the dominant metabolite cohort of a novel Australian fungus, *Aspergillus nanangensis*, *Beilstein J. Org. Chem.* 15 (2019) 2631–2643.
- [15] S. Limbadri, X.W. Luo, X.P. Lin, S.G. Liao, J.F. Wang, X.F. Zhou, B. Yang, Y.H. Liu, Bioactive novel indole alkaloids and steroids from deep sea-derived fungus *Aspergillus fumigatus* SCSIO 41012, *Molecules* 23 (2018) 2379.
- [16] C.P. Xing, J. Wu, J.M. Xia, S.Q. Fan, X.W. Yang, Steroids and anthraquinones from the deep sea-derived fungus *Aspergillus nidulans* MCCC 3A00050, *Biochem. Syst. Ecol.* 83 (2019) 103–105.
- [17] Z.M. Liu, Z.T. Dong, P. Qiu, Q.L. Wang, J.J. Yan, Y.J. Lu, P.A. Wasu, K. Hong, Z.G. She, Two new bioactive steroids from a mangrove-derived fungus *Aspergillus* sp, *Steroids* 140 (2018) 32–38.
- [18] L.A. Azeez, S. Muid, B.M. Hasnul, Identification of volatile secondary metabolites from an endophytic microfungus *Aspergillus nomius* KUB105, *Malays. J. Anal. Sci.* 20 (2016) 751–759.
- [19] C. Luz, F. Saladino, F.B. Luciano, J. Manes, G. Meca, In vitro antifungal activity of bioactive peptides produced by *Lactobacillus plantarum* against *Aspergillus parasiticus* and *Penicillium expansum*, *Lwt-Food Sci. Tech.* 81 (2017) 128–135.
- [20] X. Ma, X.H. Nong, Z. Ren, J. Wang, X. Liang, L. Wang, S.H. Qi, Antiviral peptides from marine gorgonian-derived fungus *Aspergillus* sp. SCSIO 41501, *Tetrahedron Lett.* 58 (2017) 1151–1155.
- [21] P. Klausmeyer, T.G. McCloud, K.D. Tucker, J.H. Cardellina, R.H. Shoemaker, Spirochlorine class compounds from *Aspergillus flavus* inhibit azole-resistant *Candida albicans*, *J. Nat. Prod.* 68 (2005) 1300–1302.
- [22] L.J. Ding, T. Li, X.J. Liao, S. He, S.H. Xu, Asperitaconic acids A–C, antibacterial itaconic acid derivatives produced by a marine-derived fungus of the genus *Aspergillus*, *J. Antibiot.* 71 (2018) 902–904.
- [23] A. Samie, T. Tambani, E. Harshfield, E. Green, J.N. Ramalivhana, P.O. Bessong, Antifungal activities of selected Venda medicinal plants against *Candida albicans*, *Candida krusei* and *Cryptococcus neoformans* isolated from south African AIDS patients, *Afr. J. Biotechnol.* 9 (2010) 2965–2976.
- [24] Sybly Software, Version X 2.0, Tripos Associates Inc, St. Louis, MO, 2013.
- [25] M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G.A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H.P. Hratchian, A.F. Izmaylov, J. Bloino, G. Zheng, J.L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J.A. Montgomery Jr., J.E. Peralta, F. Ogliaro, M. Bearpark, J.J. Heyd, E. Brothers, K.N. Kudin, V.N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J.C. Burant, S.S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J.M. Millam, M. Klene, J.E. Knox, J.B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, R.L. Martin, K. Morokuma, V.G. Zakrzewski, G.A. Voth, P. Salvador, J.J. Dannenberg, S. Dapprich, A.D. Daniels, O. Farkas, J.B. Foresman, J.V. Ortiz, J. Cioslowski, D.J. Fox, Gaussian 09, Revision C.01, Gaussian, Inc., Wallingford, CT, 2010.

- [26] P.J. Stephens, N. Harada, ECD cotton effect approximated by the Gaussian curve and other methods, *Chirality* 22 (2010) 229–233.
- [27] Y.S. Che, J.B. Gloer, J.A. Scott, D. Malloch, Communiols A-D: new mono- and bis-tetrahydrofuran derivatives from the coprophilous fungus *Podospora communis*, *Tetrahedron Lett.* 45 (2004) 6891–6894.
- [28] E. Liddle, A. Scott, L.C. Han, D. Ivison, T.J. Simpson, C.L. Willis, R.J. Cox, In vitro kinetic study of the squalestatin tetraketide synthase dehydratase reveals the stereochemical course of a fungal highly reducing polyketide synthase, *Chem. Commun.* 53 (2017) 1727–1730.
- [29] T. Asai, S. Morita, N. Shirata, T. Taniguchi, K. Monde, H. Sakurai, T. Ozeki, Y. Oshima, Structural diversity of new C<sub>13</sub>-Polyketides produced by chaetomium mollipilium cultivated in the presence of a NAD<sup>+</sup>-dependent histone deacetylase inhibitor, *Org. Lett.* 14 (2012) 5456–5459.
- [30] D.C. Braddock, A hypothesis concerning the biosynthesis of the obtusallene family of marine natural products via electrophilic bromination, *Org. Lett.* 8 (2006) 6055–6058.